In a report published Friday, Wunderlich Securities analyst James Terwilliger reiterated a Buy rating on Symmetry Medical, Inc. SMA, raising their price target from $10.00 to $11.00.
According to the report, “We are raising our 2014 estimates and price target for Symmetry Medical, Inc. (SMA). We are raising our 2014 revenue and adjusted EPS estimates to $417 million and $0.55 from $415 million and $0.50. Compared to our 2013 estimates, this represents 4% revenue growth and 77% adjusted EPS growth.”
Some key points from the report included:
-”We believe that revenue growth in 2014 will be driven by 6% growth in the Implant product line and 6% growth in the Cases product line.”
-”We believe that management will remain focused on reducing debt levels and we remind investors that debt has declined from $259 million at 12/31/11 to $175 currently.”
-”We believe that management will remain focused on reducing debt levels and we remind investors that debt has declined from $259 million at 12/31/11 to $175 currently.”
SMA closed Thursday at $9.77.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.